英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
inadvisably查看　inadvisably　在百度字典中的解释百度英翻中〔查看〕
inadvisably查看　inadvisably　在Google字典中的解释Google英翻中〔查看〕
inadvisably查看　inadvisably　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • New Treatments for Migraines: What Actually Works in 2025?
    In response, the American Headache Society now recommends CGRP-targeting therapies as first-line options for eligible patients, supporting broader adoption and access This article reviews the most effective migraine treatments available in 2025, focusing on their mechanisms of action, clinical evidence, and their role in modern migraine
  • FDA Approves Brekiya (dihydroergotamine mesylate) Injection . . .
    BRIDGEWATER, N J , May 15, 2025 -- Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or
  • Best New Migraine Medications and Treatments — Migraine Again
    In April 2025, the FDA approved the first prescription-based digital therapeutic for episodic migraine prevention Click Therapeutics’ CT-132 is a 12-week app-based intervention that integrates multiple evidence–based behavioral techniques, including elements of cognitive behavioral therapy (CBT)
  • Brekiya Approved for Acute Treatment of Migraine and Cluster . . .
    The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults
  • Amneal Pharmaceuticals, Inc. - Amneal Receives U. S. FDA . . .
    Brekiya ® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N J , May 15, 2025 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S





中文字典-英文字典  2005-2009